This variation in the structure of the fusion protein, i.e., the various parts of the ABL and NUP214 molecules that are included in the fusion protein, probably led to a biological and clinical heterogeneity of ABL1-NUP214 AML. This evidence concerns the gene NUP214 and acute myeloid leukemia.